Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China
SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104...
First-Mover Advantage in Central Asia's Booming Hardware Market: CAIHE 2026 Opens Exhibition Registration
TASHKENT, Uzbekistan, June 24, 2026 /PRNewswire/ -- Powered by EISENWARENMESSE – International Hardware Fair, the Central Asia International Hardware Expo (CAIHE) will debut from November 24 to 26, 2026 at the Uzexpocentre in Tashkent, Uzbekistan....
Ping An Reports Steady 7.6% Growth in Operating Profit Attributable to Shareholders of the Parent Company in Q1 2026, Life & Health NBV Increases 20.8% YoY
Group Total Assets Exceed RMB14 Trillion HONG KONG and SHANGHAI, April 28, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group"; HKEX: 2318; SSE: 601318) today announced its first quarter...
The EXCEL - First-of-its-kind study highlights critical role of essential phospholipids in improving Fatty Liver Disease
PARIS, April 27, 2026 /PRNewswire/ -- A new study has established that treatment with essential phospholipids (Essentiale) resulted in a 2.5 times greater reduction in liver fat, significant improvement in fatigue and improvement of glycaemic...
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory...
First Implant of KingstronBio's ProStyle M® Transcatheter Mitral Valve System Successfully Completed in National Multicenter Confirmatory Study
SHANGHAI, April 8, 2026 /PRNewswire/ -- On March 12, 2026, the first implant of the ProStyle M® Transcatheter Mitral Valve System (ProStyle M®) was successfully completed under pure ultrasound guidance as part of its confirmatory clinical study. The...
GameChange Solar Announces Successful Industry-First, Full-Scale Seismic Testing of Single-Axis Solar Trackers
Genius Tracker™ system completes IEEE 693 high-performance level earthquake testing at UC Berkeley's PEER Lab NORWALK, Conn., March 31, 2026 /PRNewswire/ -- GameChange Solar, a leading global supplier of solar tracker and fixed-tilt racking...
"First-listed Chinese Noodle Restaurant" Xiao Noodles Announces 2025 Annual Results
Achieving Dual Success in Scale and Profitability, with a Substantial Increase in Annual Profit Performance Highlights: Revenue: RMB1,622.4 million, representing a year-on-year increase of 40.5% Net Profit: RMB106.1 million, representing a...
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven...
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase...